Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

I covered Abeona Therapeutics Inc. (NASDAQ: ABEO ) some six years ago, and have never looked at it again since. The lead program is pz-cel (prademagene zamikeracel, formerly EB-101), “an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa.” They alsoAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software whe ...